Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

WASHINGTON, D.C. U.S. Senate Democratic Whip Dick Durbin (D-IL) sent letters to five telehealth companies that have held ...

The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully understanding the various factors affecting ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...